人淋巴母细胞干扰素和低剂量白细胞介素-2联合供体淋巴细胞输注治疗慢性粒细胞白血病第三次复发——病例报告
Lymphoblastoid human interferon and low dose IL-2 combined with donor lymphocyte infusion as therapy of a third relapse of CML--a case report.
作者信息
Lönnqvist B, Brune M, Ljungman P
机构信息
Department of Hematology, Huddinge Hospital, Sweden.
出版信息
Bone Marrow Transplant. 1996 Jul;18(1):241-2.
A patient, who was treated twice with donor lymphocyte infusions for relapse of CML after an allogeneic BMT was given lymphoblastoid human alpha-IFN after a third relapse. Further donor lymphocyte infusions were followed by repeated courses of 30 days treatment with a low dosage of IL-2 subcutaneously, alternately with alpha-IFN. This treatment resulted in a hematologic and cytogenetic remission. He also developed a limited degree of chronic GVHD. At the latest follow-up at 20 months after the third course of lymphocyte infusions he is in continuous hematologic and cytogenetic remission. Furthermore, a qualitative PCR analysis for the bcr/abl translocation is negative.
一名慢性粒细胞白血病（CML）患者在接受异基因骨髓移植（BMT）后复发，接受了两次供体淋巴细胞输注治疗。第三次复发后，给予人淋巴母细胞α-干扰素治疗。随后进一步进行供体淋巴细胞输注，并交替皮下注射低剂量IL-2和α-干扰素，每次30天，重复多个疗程。该治疗导致血液学和细胞遗传学缓解。他还出现了程度有限的慢性移植物抗宿主病（GVHD）。在第三次淋巴细胞输注疗程后20个月的最新随访中，他处于持续的血液学和细胞遗传学缓解状态。此外，bcr/abl易位的定性PCR分析为阴性。
Zotero 插件